本报记者 陈 曦 日前，天津医科大学肿瘤医院研发的全国首个肿瘤重症全程数字化管理专科系统（以下简称"数字化系 统"）正式上线。依托该系统打造的智慧肿瘤重症诊疗场景、智慧医疗管理场景和智慧医学科研场景正 在改变肿瘤重症医学的临床治疗方式、质控管理方式和科研方式。 医生的"得力帮手" 来源：科技日报 肿瘤重症全程数字化管理专科系统在天津医科大学肿瘤医院投入使用。 【应用选萃】 精明的"数据管家" "在传统肿瘤重症诊疗场景中，重症监护室里的医生和护士就像数据搬运工，每日都面临着繁重的手工 记录工作。"天津医科大学肿瘤医院重症监护科主任王东浩回忆道，"人工获取数据不仅耗费大量时间和 精力，还容易出现遗漏与失误，难以为医疗决策提供可靠参考，给肿瘤治疗带来了诸多不确定性。" 如今，在智慧肿瘤重症诊疗场景下，数字化系统成了医生的"第三只眼"。 天津医科大学肿瘤医院重症监护科主任王东浩与团队分析系统数据。受访者供图 数字化系统实现了全域数据整合，可自动抓取床旁监护仪、呼吸机等设备数据，以及患者生命体征、病 情变化数据，并同步整合医院信息系统、实验室信息系统、医学影像存档与通信系统中的检验结果和影 像报告。一旦监测到异常数值， ...

Core Viewpoint - The Hong Kong stock market's positive performance reflects a global capital reallocation towards Asia-Pacific assets, particularly in the higher vocational education sector, which benefits from both consumer demand and policy incentives [1] Group 1: Financial Performance - In the first half of the 2025 fiscal year, the company achieved revenue of approximately 1.247 billion RMB, a year-on-year increase of 7.5%, driven by growth in student numbers and tuition fee increases [2] - The company’s student enrollment exceeded 100,000, marking a 4.4% increase compared to the previous year, with revenue growth from 554 million RMB in the first half of 2021 to 1.247 billion RMB in the first half of 2025, representing a cumulative increase of 125.27% [2] - The company maintains a healthy financial structure with a debt-to-asset ratio of only 44.44% and cash and cash equivalents amounting to 2.071 billion RMB [4] Group 2: Shareholder Returns - The board proposed an interim dividend of 0.066 HKD per share, with a payout ratio of 30%, marking the twelfth dividend distribution since the company went public [4] - Over the past three years, the total cash dividends exceeded 570 million RMB, demonstrating a commitment to returning value to shareholders [4][6] Group 3: Market Outlook - The company is optimistic about the development opportunities in the Guangdong-Hong Kong-Macao Greater Bay Area over the next 15 years, anticipating a significant demand for high-quality applied talent [6][10] - The Guangdong Provincial Education Department projects a 50% increase in student enrollment by 2035, with the company’s nine institutions forming a strategic network to meet diverse educational needs [9] Group 4: Strategic Initiatives - The company is actively enhancing its educational infrastructure and resources, including the acquisition of new educational land and the optimization of campus facilities [11] - It is focusing on integrating cutting-edge fields such as AI, new energy vehicles, and smart healthcare into its curriculum, collaborating with industry leaders to create a comprehensive talent training system [12][13] - The company aims to upgrade traditional disciplines to align with market demands, ensuring that its educational offerings remain relevant and competitive [13][14]

Core Viewpoint - Tianzhihang, a leading domestic surgical robot company, reported a narrowing loss in 2024 and a significant revenue growth of 102.40% in Q1 2025, indicating a recovery in the surgical robot market driven by increasing surgical volumes and optimized revenue structure [1][2][3]. Financial Performance - In 2024, Tianzhihang achieved operating revenue of 179 million yuan, with a net profit loss of 121 million yuan, a 22.54% improvement from a loss of 156 million yuan in 2023 [2]. - The company reported a revenue of 58.58 million yuan in Q1 2025, up from 28.94 million yuan in the same period of 2024, marking a year-on-year growth of over 102.40% [2]. Surgical Application Growth - The Tianji orthopedic surgical robot completed over 39,000 surgeries in 2024, a 62.5% increase from over 24,000 surgeries in 2023 [3]. - By the end of Q1 2025, the cumulative surgical volume exceeded 110,000 cases, reflecting a steady market demand [3]. Revenue Structure Optimization - Revenue from supporting equipment and consumables reached 54.86 million yuan in 2024, a year-on-year increase of 28.52%, while technical service revenue was 42.96 million yuan, up 104.26% [3]. - The proportion of these two revenue streams increased from approximately 30% in 2023 to 54.7% in 2024, indicating a shift towards more stable and recurring income sources [3]. Industry Landscape - The surgical robot industry is recognized as a key sector in smart healthcare, with a projected global market size of 63.12 billion USD by 2030 and a potential market size of 70.85 billion yuan in China, with a compound annual growth rate exceeding 30% [4]. - As of the end of 2024, 64 companies had 115 surgical robot products approved in China, with orthopedic surgical robots accounting for 47% of the total, indicating intense competition [4]. Product Development and Innovation - Tianzhihang has established a product development framework of "pre-research generation, conversion generation, and上市 generation," enhancing its continuous innovation capability [6]. - The company has expanded its orthopedic surgical robot product line to cover major orthopedic procedures, including total hip and knee replacements, reflecting progress in product platform development [6]. Market Expansion and Strategy - Tianzhihang has maintained its leading market share in the domestic orthopedic surgical robot market and has received CE certification for its orthopedic navigation systems, facilitating overseas market expansion [7]. - The company is implementing differentiated pricing strategies to cater to various levels of medical institutions, enhancing its adaptability in the market [7].

Core Viewpoint - Omron has established itself as a leader in health care devices, particularly in blood pressure monitors, and is expanding its innovative technologies to address cardiovascular risks, particularly atrial fibrillation [1][6][8]. Group 1: Company Overview - Omron established its first factory in China in 1993, making the Dalian facility the largest global production base for Omron's health care division [1]. - The company operates in four major business areas: health care, industrial automation, electronic components, and social solutions [2]. Group 2: Innovative Technology - The "Intellisense Afib" technology allows blood pressure monitors to simultaneously detect the risk of atrial fibrillation during blood pressure measurement [8]. - This technology is based on 50 years of pulse wave data and integrates AI to enhance the accuracy of atrial fibrillation detection [8]. Group 3: Market Position and Strategy - China accounts for 33% of Omron's global health care sales, highlighting its significance as a key market [6]. - The aging population and the rise of health-conscious younger generations present substantial growth opportunities for Omron's products [6]. Group 4: Product Development - The new generation blood pressure monitor, HCG-7800T, improves accuracy and ease of use, allowing for simultaneous blood pressure and atrial fibrillation detection [9]. - Omron has sold over 350 million home blood pressure monitors globally as of April 2023, indicating strong market penetration [11]. Group 5: Future Vision - Omron aims to achieve three zeros in its health care business: zero occurrences of cardiovascular events, zero deterioration of respiratory diseases, and zero limitations in daily life due to chronic pain [14].

Group 1 - The Hang Seng Medical Index ETF experienced a turnover of 8.47% during the trading session, with a transaction volume of 21.38 million yuan [3] - The ETF's scale increased by 18.48 million yuan over the past week, indicating significant growth [3] - The ETF's shares grew by 10 million shares this month, reflecting substantial growth [3] Group 2 - The current price-to-earnings ratio (PE-TTM) of the Hang Seng Medical Index ETF is 24.86, which is at a historical low, being in the 6.5% percentile over the past year [3] - A joint implementation plan for the digital transformation of the pharmaceutical industry has been issued by seven government departments, aiming for significant progress by 2027 [3] Group 3 - Short-term AI medical themes are expected to continue being a focus, with market attention shifting towards Q1 performance and potential improvements in the pharmaceutical industry by Q2 2025 [4] - The top ten weighted stocks in the Hang Seng Medical Index account for 57.69% of the index, including companies like BeiGene, WuXi Biologics, and JD Health [4] - Investors without stock accounts can access the Hang Seng Medical Index ETF through a linked fund for investment opportunities in the Hong Kong medical sector [4]

Core Viewpoint - Tsinghua University has established an Artificial Intelligence Hospital aimed at transforming the medical model through AI integration, enhancing healthcare efficiency, and addressing the shortage of general practitioners [1][2]. Group 1: Hospital Development - The construction of the AI hospital will be phased, initially relying on Tsinghua University’s AI capabilities and interdisciplinary medical engineering collaboration, with pilot programs in general medicine and specialized fields such as ophthalmology and radiology [1]. - The long-term goal is to operationalize the AI hospital, promoting a disruptive change in healthcare delivery [1][2]. Group 2: AI Integration in Healthcare - The AI hospital aims to break the traditional "hospital + AI" model by embedding AI functionalities into clinical services, assisting doctors in precise decision-making, improving service efficiency, and reducing operational costs [2]. - The hospital will serve as a key platform for medical education and training, fostering a new generation of "AI collaborative doctors" [2]. Group 3: Research and Innovation - Tsinghua University’s Intelligent Industry Research Institute emphasizes that AI is a critical engine of the Fourth Industrial Revolution, with smart healthcare being a significant area of research and application [3]. - The "Zijing AI Doctor" system, developed by Tsinghua's team, is set to enhance the evolution of AI doctors, laying a foundation for the AI hospital's construction [3]. - An academic clinical center has been launched to promote the integration and standardization of medical resources, focusing on collaborative development in medical education and research [3].

华为与中山七院共建"鲲鹏+昇腾"自主创新平台，将实现医院业务系统、数据库及ICT基础设施的智能 化。创新中心通过AI驱动影像质控优化、远程智能诊疗探索、智慧化病区管理升级及AI辅助临床决策 优化，打造覆盖诊疗全流程的智能化解决方案。 中山七院院长何裕隆强调，智慧医院是公立医院高质量发展的必由之路，此次合作是院企技术整合的典 范，期待通过共建创新中心，实现"优质资源全域共享"。 深圳商报•读创客户端记者 陈姝 4月23日，中山大学附属第七医院（以下简称"中山七院"）与华为技术有限公司（下文简称"华为"）签 署全面合作协议，并与联影医疗技术集团有限公司、深圳市联新移动医疗科技有限公司（以下简称"联 影""联新"）在深圳共同签署三方合作协议，合作共建"中山大学附属第七医院智慧医疗联合创新中 心"（以下简称"创新中心"）。 揭牌仪式（活动主办方供图） 创新中心将采用即将建成的10.0P级医疗人工智能算力中心，通过产学研医深度融合，推动智慧医疗自 主创新，促进医院高质量发展，助力国家实施"健康中国"战略。 在揭牌仪式上，中山七院副院长魏富鑫表示，此次的合作亮点是通过技术赋能，破解临床痛点。此次合 作以打造"三位一体"智 ...

本报讯 （记者李勇）4月25日，辽宁何氏眼科医院集团股份有限公司（以下简称"何氏眼科"）发布《2024年环境、社会和 公司治理（ESG）报告》，从多个维度全面展示过去一年公司在ESG领域的布局与实践成果，以及在打造"智慧光明城"，推动 可持续发展道路上的坚定决心与积极作为。 （编辑 张伟） 自创立以来，何氏眼科始终以科技创新为引领，秉持"奉献社会、百姓信赖、创新引领、共创幸福"的核心价值观和"科技 人文"的经营理念，坚持"预防为主、防治结合"的服务理念，依托创新技术和专业人才，为各类眼病患者提供眼科全方位诊疗 服务。公司在白内障、青光眼、玻璃体视网膜病变、干眼症、中医眼科、屈光不正等诊疗领域积累了丰富的临床经验和技术优 势。 报告显示，何氏眼科围绕"健康中国"战略方向和全球眼健康总体方向，以构建"智慧光明城"为战略目标，积极推进医疗健 康产业线上线下融合布局。依托独有的眼健康全产业链生态平台优势，借助大数据、人工智能、基因技术、干细胞技术等创新 手段，通过精准医疗和智慧医疗赋能，为患者提供数字化、全方位、全场景、全生命周期的眼健康管理服务新模式。公司坚持 以人为本，注重激发员工潜能与归属感，打造安全、公平、关 ...

Core Insights - The company reported a revenue of 549 million yuan and a net profit attributable to shareholders of -21.30 million yuan for the year 2024 [1] - The company is positioned as a comprehensive provider of smart city, smart healthcare, and digital energy solutions, focusing on safety, intelligence, sustainability, and health [3] Smart City Initiatives - The company participated in the top-level design of smart buildings and completed the group standard "Smart Building Evaluation Standard," showcasing its capabilities in complex project implementation [1] - The company signed a supplementary agreement for the high-rise project in Chengdu Tianfu New Area, reinforcing its leading position in the smart commercial real estate sector [1] - The "Smart Town Precision Service System Construction" project won the Shanghai Quality Technology Progress Award [1] Cloud Platform Development - The company initiated projects such as the "Smart Building AIoT Platform" and "Smart Health Cloud Platform" to meet the digital upgrade needs of smart buildings [1] - Initial work on the Feicheng Digital Village Big Data Platform has been completed, and a project in Putuo District is in the final acceptance stage [1] Healthcare and R&D Achievements - The healthcare segment achieved breakthroughs in research and technology development, collaborating with the University of Electronic Science and Technology on various projects [2] - The company established close partnerships with major domestic manufacturers and achieved compatibility certifications for its products, ensuring stability and performance [2] - In 2024, the company invested 34.46 million yuan in R&D, applied for 29 software copyrights, and obtained 23 software copyright certificates and 8 invention patent authorizations [2] - The company released several low-code development tools, enhancing system and interface development efficiency [2]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000516 证券简称：国际医学 公告编号：2025-010 西安国际医学投资股份有限公司2024年年度报告摘要 一、重要提示 本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投资者 应当到证监会指定媒体仔细阅读年度报告全文。 所有董事均已出席了审议本报告的董事会会议。 非标准审计意见提示 □适用 √不适用 董事会审议的报告期利润分配预案或公积金转增股本预案 □适用 √不适用 公司计划不派发现金红利，不送红股，不以公积金转增股本。 董事会决议通过的本报告期优先股利润分配预案 1、公司简介 ■ 2、报告期主要业务或产品简介 （一）主要业务 公司以大健康医疗服务和现代医学技术转化应用为主业。目前，正在运营西安高新医院、西安国际医学 中心医院等综合性医疗机构。在医疗领域，公司探索并发展了"综合医疗+特色专科"创新业务模式，旨 在满足广大群众多元化医疗健康需求，充分发掘综合性医疗机构的协同效应。一方面致力于提供高质量 普惠型医疗服务，成功打造了脑科、心血管、消化、胸科、肿瘤、血液病、骨科等多个优势专科，开展 了一系列技术含 ...